MowOot and Trans-anal Irrigation fOr coNstipation (MOTION)

Intermittent Colonic Exoperistalsis Treatment With MOWOOT Medical Device to Treat Chronic Constipation in Adult Patients Waiting for Using Trans-Anal Irrigation: A Pilot Study

This prospective, open-labelled, longitudinal, controlled study aims to evaluate the suitability of Intermittent Colonic Exoperistalsis (ICE) treatment for adults with refractory chronic constipation who are awaiting trans-anal irrigation (TAI). The ICE treatment will be applied using the MOWOOT device (USMIMA). The study involves two treatment groups: an experimental group receiving daily ICE treatments and a control group following standard TAI care. Participants will serve as their own controls in pre- and post-treatment analyses to assess changes in bowel management satisfaction and other outcomes.

Study Overview

• Status: Recruiting
• Conditions: Constipation Chronic Idiopathic
• Intervention / Treatment: Device: ICE Treatment; Procedure: TAI Standard-of-Care Treatment

Detailed Description

This study is a prospective, open-labelled, longitudinal, controlled trial conducted at a single center. It aims to assess the suitability of Intermittent Colonic Exoperistalsis (ICE) treatment for bowel management in adults with refractory chronic constipation who are awaiting trans-anal irrigation (TAI). The ICE treatment will be applied using the MOWOOT device (USMIMA). The study includes two treatment groups:

Experimental ICE Group: Participants will receive one ICE treatment session lasting 20 minutes daily, at the same hour, for 12 weeks.

Control TAI Group: Participants will follow the usual TAI standard-of-care treatment for 12 weeks.

Participants will be given the option to choose between the ICE treatment and the TAI treatment after both options are explained to them. Healthcare professionals will recommend the most suitable treatment based on individual patient needs, but the final decision will rest with the patients.

The primary objective is to evaluate the change in satisfaction with daily quality of life related to bowel management, measured by a Likert scale (Bothersome scale). Secondary objectives include assessing the efficacy of the ICE treatment on chronic constipation, both qualitatively and quantitatively, and evaluating the economic impact from the hospital's perspective.

Secondary outcomes will be measured through various patient-reported and health professional-reported metrics, including changes in quality of life (PAC-QOL), constipation symptoms (PAC-SYM), constipation severity (CCCS), time spent in bowel management and evacuation, use of other treatments, number of consultations and hospital admissions, productivity, acceptability and ease of use of the ICE treatment, reported problems, compliance, adherence, and persistence in treatment. Health professional outcomes will include time spent per visit, total time spent until independent use of MOWOOT, ease of patient management, and patient treatment preferences.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Immaculada Herrero-Fresneda, PhD; Phone Number: +34 935106653; Email: ihf@mowoot.com

Study Locations

• United Kingdom
  • London
    • London, London, United Kingdom, NW10 7NS
      • Recruiting
      • The Sir Alan Parks Physiology & Pelvic Floor Biofeedback Unit., Central Hospital, Department of Physiology, St Mark's Hospital, The National Bowel Hospital
      • Contact: Alex Bortolotti; Phone Number: 020 8963 7189; Email: enquiries@trustplus.co.uk
      • Sub-Investigator: Tatenda Marunda

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adult people (18 yo or older) of any gender
2. Attending their pre-scheduled on-site visit to the site (The Sir Alan Parks Physiology & Pelvic Floor Biofeedback Unit | Central Middlesex Hospital) due to constipation (Symptoms meeting the American College of Gastroenterology definition of chronic constipation: unsatisfactory defaecation characterized by infrequent stool, difficult stool passage or both for at least previous 3 months.
3. Bothered by their constipation
4. Failed biofeedback (in absence of outlet problems)
5. In waiting list to use TAI
6. Able to undertake the treatment with the MOWOOT device or TAI themselves, or with a carer willing to do it
7. Able to understand the study requirements
8. Able to understand written and spoken English (due to questionnaire validity)
9. Able and willing to provide written informed consent to participate

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

Disease phenotype exclusion criteria:

• Irritable Bowel Syndrome with Diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBSmix): (not due to laxative use)
• Inflammatory Bowel Disease (IBD)
• Significant outlet problem
• Trapping rectocele
• Intra anal rectal intussusception
• External rectal prolapse

Device-related exclusion criteria:

• Abdominal perimeter ≤65cm or ≥130cm
• Unable to independently use the MOWOOT technology, unless a carer is available daily to assist

Other medical conditions, medications and contraindications:

• Pregnancy or attempt to become pregnant in the next 6 months.
• Previous large bowel resection
• Active anorexia or bulimia
• Active abdominal cancer
• Large inguinal or umbilical hernia
• Recent abdominal scars, abdominal wounds or skin disorders that may make abdominal massage uncomfortable
• Any condition that contraindicates abdominal massage.
• Significant abdominal pain
• Participation in another parallel interventional clinical trial or less than 2 months from participation in a previous interventional clinical trial
• Planned surgery* if it might be within trial dates (* minor surgery not affecting adherence to treatment is allowed)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental ICE Group; Each patient will receive 1 ICE treatment of 20 minutes at least once per day, every day at the same hour, during the intervention period of 12 weeks.	Device: ICE Treatment; Each patient in the Experimental ICE Group will receive one Intermittent Colonic Exoperistalsis (ICE) treatment session lasting 20 minutes. These sessions will be conducted at least once per day, every day at the same hour, for a total duration of 12 weeks. The ICE treatment involves using the MOWOOT medical device designed to alleviate chronic constipation by stimulating colonic peristalsis.
Active Comparator: Control TAI Group; Each patient will follow the usual TAI standard-of-care treatment for the intervention period of 12 weeks.	Procedure: TAI Standard-of-Care Treatment; Each patient in the Control TAI Group will follow the usual Trans-Anal Irrigation (TAI) standard-of-care treatment. This involves the regular use of TAI procedures as prescribed by healthcare professionals for the intervention period of 12 weeks. The TAI treatment is a well-established method for managing chronic constipation by mechanically clearing the bowel.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Satisfaction with Daily Quality of Life Related to Bowel Management	Assessed by the Bothersome Scale (a Likert scale) where 0 is 'not at all' and 10 is 'a great deal,' with higher scores indicating a worse outcome	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in Quality of Life According to PAC-QOL Score	Assessed by the PAC-QOL (Patient Assessment of Constipation Quality of Life) scale, where higher scores indicate a worse quality of life.	12 weeks
Changes in Constipation Symptoms According to PAC-SYM Score	Measured using the PAC-SYM (Patient Assessment of Constipation Symptoms) scale, with higher scores reflecting more severe constipation symptoms	12 weeks
Changes in Constipation Severity According to CCCS	Evaluated by the CCCS (Constipation Clinical Severity Scale), where higher scores denote greater severity of constipation	12 weeks
Change in Time Spent in Bowel Management	Measured in minutes per day, data from bowel diaries.	12 weeks
Change in Time Spent in Evacuation	Measured in minutes per day, data from bowel diaries.	12 weeks
Change in Use of Other Treatments (e.g., Laxatives, Suppositories)	Data from patient surveys.	12 weeks
Change in Number of Consultations to Primary Care (GP, Nurse)	Data from patient surveys.	12 weeks

Collaborators and Investigators

• Sponsor: usMIMA S.L.
• Investigators: Principal Investigator: Gregory Thomas, MD, PhD, The Sir Alan Parks Physiology & Pelvic Floor Biofeedback Unit | Central Middlesex Hospital

Study record dates

Study Major Dates

• Study Start (Actual): June 25, 2025
• Primary Completion (Estimated): July 31, 2026
• Study Completion (Estimated): September 1, 2026

Study Registration Dates

• First Submitted: February 12, 2025
• First Submitted That Met QC Criteria: February 18, 2025
• First Posted (Actual): February 19, 2025

Study Record Updates

• Last Update Posted (Actual): January 22, 2026
• Last Update Submitted That Met QC Criteria: January 20, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: constipation; transit problems; Trans-Anal Irrigation; Intermittent Colonic Exoperistalsis
• Additional Relevant MeSH Terms: Signs and Symptoms, Digestive; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Constipation
• Other Study ID Numbers: MOW-08-2024

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No